drugset
drugset / Trial / NCT04177082

Safety and Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution

NCT04177082 ↗

Phase 1 Completed 200 enrolled Cornea Associates of Texas
RandomizedParallel-groupOpen-labelTreatment

Summary

Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Collagen Cross-linking in Eyes With Corneal Thinning Conditions

Timeline

Start
2020-01-10
Primary completion
2022-05-05
Completion
2022-05-05

Drugs

EvaluationDrugModalityDoseRoute
Background Riboflavin Other / unclassified — —

Indications

corneal degeneration corneal ectasia keratoconus pellucid marginal degeneration